Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation

Preclinical Childhood Tumor Models: Drug Efficacy Biomarker Identification and Validation

Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are...

Full description

Bibliographic Details
Main Authors: Brian eGeier, Dias eKurmashev, Raushan T Kurmasheva, Peter J Houghton
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-08-01
Series:Frontiers in Oncology
Subjects:
Data Mining
bioinformatics
xenografts
childhood cancer
Preclinical Pharmacology
Human tumor xenografts; drug sensitivity; expression profiling; copy number variation; elastic net; long-intergenic non-coding RNA’s
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00193/full
Description
Summary:Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents, and ‘omics’ approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.
ISSN:2234-943X

Similar Items